UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,731	04/26/2005	Serge Auvin	427.095	6471
	7590 06/13/200 COSTIGAN P.C.		EXAMINER	
1185 AVENUE	OF THE AMERICAS		HABTE, KAHSAY	
NEW YORK, NY 10036			ART UNIT	PAPER NUMBER
			1624	
			MAIL DATE	DELIVERY MODE
			06/13/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/532,731	AUVIN ET AL.
Notice of Allowability	Examiner	Art Unit
	Kahsay T. Habte	1624
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313	ears on the cover sheet w (OR REMAINS) CLOSED or other appropriate comm IGHTS. This application is	rith the correspondence address in this application. If not included nunication will be mailed in due course. THIS
1. This communication is responsive to <u>06/04/2008</u> .		
2. ☑ The allowed claim(s) is/are <u>1-4</u> .		
3. ☑ Acknowledgment is made of a claim for foreign priority un a) ☑ All b) ☐ Some* c) ☐ None of the: 1. ☑ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority do	e been received. e been received in Applicati	on No
International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give	MENT of this application. itted. Note the attached EX	(AMINER'S AMENDMENT or NOTICE OF
5. CORRECTED DRAWINGS (as "replacement sheets") mus	st be submitted.	
(a) ☐ including changes required by the Notice of Draftspers	son's Patent Drawing Revie	ew (PTO-948) attached
1) ☐ hereto or 2) ☐ to Paper No./Mail Date	•	
(b) ☐ including changes required by the attached Examiner' Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the state of the sheet.	.84(c)) should be written on	the drawings in the front (not the back) of
DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MAT	ERIAL must be submitted. Note the
Attachment(s)	5 Notice of I	nformal Patent Application
 Notice of References Cited (PTO-892) Dotice of Draftperson's Patent Drawing Review (PTO-948) 	<u> </u>	Summary (PTO-413),
3. ☐ Information Disclosure Statements (PTO/SB/08),	Paper No	./Mail Date s Amendment/Comment
Paper No./Mail Date4.		s Statement of Reasons for Allowance
of Biological Material	9.	

Application/Control Number: 10/532,731 Page 2

Art Unit: 1624

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Charles Muserlian on June 5, 2008. Enter the following:

Replace claims 3-4 in the claim set (06/04/2008) with

Claim 3 (previously presented) A compound of claim 1, wherein

• R¹, R², R³, R⁵ and R⁶ are independently selected from the group consisting of hydrogen alkyl and alkoxy;

- R³ is hydrogen or methyl;
- ♦ W is -O- or -S-;
- X is -Y-CO- or -O-Y-CO-:
- ◆ -(AA)_n- is an -(AA²)-(AA¹)- such that AA¹ is Leu and AA² is an ammo acid
 chosen from the group consisting of natural amino acids, 3-methylvaline,
 norvaline, phenylglycine, vinylglycine and 2-aminobatyric acid;
- R is hydrogen,

or a salf (barcof).

Application/Control Number: 10/532,731 Page 3

Art Unit: 1624

Claim 4 (previously presented)

A compound of claim 1 is selected from the

group consisting of:



- N-(10H phenothiazin-2-ylcarbonyl)-L-leucyl L leucyl \mathbb{N}^1 [(3S) 2-methoxytetiahydrofuran-3-yl]-L leucinamide;
- N-(10H-phenothiszin-2-ylearbonyl)-L-leucyl-L-leucyl-N 1 -[(3S)-2-hydroxyletrahydrofinan-3-yl]-L-leucinstnide;
- N-(10H-phonothiazin-2-yicarhonyl)glycyl-N 1 -[(3S)-2-methoxytetrohydrofuran 3-yl]-Leicucinamide;
- N-(10H-phenothiazin-2-yicarbonyl) leucyl N^{T} [(3S)-2-methoxytetrshydrofuran-3-yi]-L-leucina mide;
- \mathbb{N}^6 -[(benzyloxy)carbonyl]- \mathbb{N}^2 -(10H-phenothiszin-2-ylearbonyl)lysyl- \mathbb{N}^4 -[(3S)-2 methoxyletrahyðrofttran-3-yl]-L-leucinsmide;
- 1-(10H-phenothiazin-2-ylcorbonyi)-L-prolyl \mathbb{N}^1 -[(3S) 2-methoxytetrshydrofuran-3-yl]-L-leucinamide;

```
- N (10H-phonothiazin-2-ylcarbonyl)glycyl-N^{1}-[(3S)-2-hydroxytetishydroxuran-3-yl]
                  Lelencinamide;
                -N-(10H-phenothiozin-2-ylcarbonyl) leucyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yl]-10H-phenothiozin-2-ylcarbonyl) leucyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yl]-10H-phenothiozin-2-ylcarbonyl) leucyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yl]-10H-phenothiozin-2-ylcarbonyl) leucyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yl]-10H-phenothiozin-2-ylcarbonyl) leucyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yl]-10H-phenothiozin-2-ylcarbonyl) leucyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yl]-10H-phenothioan-3-yl]-10H-phenothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yl]-10H-phenothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yl]-10H-phenothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydrothioan-3-yllarbonyl-N^1-[(3S)-2-bydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrahydroxy(etrah
                  L-leucinsmide;
                        N-\{(10H-phenothiazin-2-yloxy)acetyl\}-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxy)acetyl\}-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxy)acetyl]-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxy)acetyl]-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxy)acetyl]-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxy)acetyl]-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxy)acetyl]-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxy)acetyl]-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxy)acetyl]-I.+alanyl-N^I+[(3S)-2-methoxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-phenothiazin-2-yloxyletrahydrofuran-ph
            B-yll-L-leucinamide;
          - N-I(10H-phenothiszin-2-yloxy)acetyiI-L-valyI-N^I-I(3S)-2-methoxytetrshydrofirm-
              3-yl]-L-leucinamide;
        -N-[(10H-phenothiazin-2\cdot yloxy)acctyl]-\beta-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-\beta-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-\beta-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-\beta-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-\beta-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-\beta-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-b-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-b-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-b-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-b-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-b-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-b-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-b-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl]-b-alanyl-N^{1}-[(3S)-2-methoxytetrahydrofuran-phenothiazin-2\cdot yloxy)acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acctyl-acct
            3-yl]-L-leucinamide;
      - N\text{-}methyl\text{-}N\text{-}[(10H\text{-}phenothiazin-2\text{-}yloxy)acetyl]glycyl-
      \mathbb{N}^{1}-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-leucinamide;
      -N-|(10H-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl]-D-valyi-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxy)acetyl-N^{1}-|(3S)-2-methoxytetrahydrofiaran-phonorbiaz in-2-yloxytetrahydrofiaran-phonorbiaz in-2-yloxytetrahy
      3-yi]-L-leucinamide:
      - 3-methyl-N-[(10H-phenothiozin-2-yloxy)acetyl]-L-valyl-
      N^{1}-[(3S)-2-methoxytetrahydrofuran-3-yl]-L-icucinamide;
      -N^{1}-[(38)-2-methoxytetrahydrofuran-3-y]]\cdot N^{2}-((28)-2-\{[(101)-phenothiazin-2-y]oxy)-1-((28)-2-((101)-phenothiazin-2-y]oxy)-1-((28)-2-((101)-phenothiazin-2-y]oxy)-1-((28)-2-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-phenothiazin-2-y]oxy)-1-((101)-
        acctyl]amino}butanoyl)-L-leucinamide;
    - N-{(10H-phonothiazin-2-yloxy)acetyl}-L-norvalyl-N^{1}-[(3S)-2-
  methoxytetrahydrofuran-
    3-yl]-L-leucinamide;
  - N-[(10H-phenothiazin-2-yloxy) acetyt] - 1-scryi-N^1-[(3S)-2-methoxytetraliydrofurun-2-yloxy) - 2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-yloxyi-2-y
    3-yl]-L-leucinamide;
  - N-[(10)]-phenothiazin-2-yloxy)acetyl]-L-threony) \mathbb{N}^4-[(38)-2-
  methoxyletraliydrofurau-
  3-yl]-Lalmeinamides
- \mathbb{N}^1 {(3S)-2-methoxyretrahy6rofuran-3-yl]-N^2-((2S)-2-{[(10H-phenothiozin-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2S)-2-yl]-N-2-((2
2-yloxy/acetyl]amino}-2-phenylethanoyl)-L-leuc/namide;
- N^1-[(3$)-2-methoxytetrahydrofuran-3-yl]-N^2-((2$)-2-{[(10H-phenothiazin-1-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$)-2-yl]-N^2-((2$
  2-yloxy)acetyl]amino}but-3-enoyf)-L-leucinamide;
```

```
~ 2-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]alenyl-
          N^2-[(3S) 2-methoxyletrallydrofuran-3-yl]-L lenefnamide;
           -N^6 - \{(benzyloxy) carbonyl] - N^2 - (10) H-phenothiazin-2-ylearbonyl pysyl-phenothiazin-2-ylearbonyl pysyl-phenothiazin-2-
           N^{1}-[(3S)-2-hydroxytettahydrofuran-3-yl] L leucinamide;
       '- 7-(10P) phenothiazin-2-γlcarbonyl) L-prolyl-N'-[(3S)-2-llydroxytetrahydrofuran-
           3-yl]-L-lencinamide;
     -N-(10 H-pheno(hiazin-2-ylearbonyl)] eucyl-N^1-((3S)-2-(acetyloxy)+tetrahydrofuran-10 H-pheno(hiazin-2-ylearbonyl)] eucyl-N^1-((3S)-(acetyloxy)+tetrahydrofuran-10 H-pheno(hiazin-2-ylearbonyl)] eucyl-N^1-((3S)-(acetyloxy)+tetrah
      3-yl]-L-leuernamide;
           N^2 - (10 H-phenothiazin-2-ylesibonyl)] ysyl-N^1 - [(3S) \ 2 \ hydroxytetrahydrofuran-3-yl] - [(3S) \ 3 \ hydroxytetrahydrofuran-3-yl] - [(3S) \ 3 \ hydroxytetrahydrofuran-3-yl] - [(3S) \ 3 \ hydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrahydroxytetrah
      L-lencinamide.
    - N-(1001-phenothiazin-2-ylacetyl)-\hat{L}-leucyl-N'-[(38)-2 methoxytetrahydrofuran-3-yl]-
     Lalencinamide;
           O-(tert-butyl)-N-(101)-phonothrazin-2-ylacetyl)-L-seryl-
    N^{T}[(3S)-2\operatorname{-methoxytetrahydroffuran-3-yl}]-L-leneinsimide;
    - N-(10H-phenothiazin 2-ylocetyl)-L-alanyl-3-cyclohexyl-
    N. -[(3S)-2-methox ytetrahydrofuran-3-yll-1 -alaninamide;
    - N-(10H-phenothiszin-2-ylacetyl)-L-leucyl-N<sup>1</sup>-[(3S) 2 hydroxytotrahydrofuran-3-yl]-
   Lelencinamide;
   - O-(tert-buryl)-N-(10H-phenorhiazin-2-ylacetyl)-L-seryl-
  N<sup>1</sup>-[(3S) 2-hydroxyfotrabydrofitran-3-yl]-L-leucinamide;
  > N-(10H-phenothiazin-2-ylaceryl)-1>alanyl-3-cyclohexyl-
  N-[(3S)-2-hydroxyterrahydrofuran-3-yl]-L-alaninamide;
  - N-[3-(10H-phenothiszin-2-yl)propanoyl]-L-leucyl-
  N^{1}-[(32)-2-methoxy(evahydrofuran-3-yt] \mathbb{L} leucinam)de;
  - N-[3-(10H-phenoth/azin-2-yi)propanoyi]-L-jeucyj-
 \mathbb{N}^{1}-\{(3S)-2-hydroxyteirahydrofuran 3-yl]-L-leucinamide;
- N-[(10H-phemothiazin-2-yloxy)acetyl]-L leucyl-N1-[(3S) 2 methoxytetrahydrofuran-
3-yl]-Lleucinamide;
- N-I(0014-pheno(hiszin-2-yluxy)acetyl]-glycyl-N^4-[(3$)-2-methoxyteirahydrofuran-
3-yl]-L-leucinamide;
```

Application/Control Number: 10/532,731

- N-[(10H-phenothiazin-2-yloxy)acetyl |-glycyl-N 1 -[(38)-2-methoxytetraliyd.
ofuran-3-yl]-L-valinamide;
- N-[(10H) phenothiazin-2-yloxy)acetyl]-glycyl-3-cyclohexyl- N 3 -[(3S)-2-methoxyletraliydrofuran-3-yl] L-alaninamide;
- N-[(10H-phenothiszin-2-yloxy)acetyl]-glycyl-N-[(3S)-2-methoxytetrahydrofuran-3-yl]-l-phenylalaninamide;
- N-[(1011-phenothiszin-2-yloxy)scetyl]glycyl-N²-isobutyl-
- \mathbb{N}^{1} -[(3S)-2-methoxytetrohydrofuran-3-yljgiydinamide;
- N-[(1011-phenothiazin-2-yloxy)acetyl]-L-lencyl \mathbb{N}^3 -[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-lencinamide;
- N-[(10H-phenoth)azin-2-yloxy)acetyl]-glycyl-N 1 [(3S)-2-hydroxyle(rahydrofuran-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-a)anyl-N $^{\rm I}$ [(3S)-2-hydroxytetralaydrofuran 3-yl]-L-leucinamide;
- N-[(10H-phenothiagin-2 yloxy)acetyl]-L-valyl-N 1 -[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-feucinamide;
- $-N-[(16H-phenothiazin-2-yloxy)acetyl]-\beta-alanyl-N^1-[(3S)-2-hydroxytetrahydroffiren-3-yl]-L-leneinamide;\\$
- N-methyl-N-[(10H-phenothiazin-2-yloxy)acetyf]giyeyl- N^3 -[(3S)-2-hydroxytetrahydrofman-3-yl]-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-D-valyl-N 1 -[(3S)-2-hydroxytetrahydroflwan-3-yl]-L-leucinamide;
- 3-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]-L-vslyl- \mathbb{N}^{1} -[(3S)-2-hydroxyletisliydrofuran-3-yl]-L-leneinamide;
- N^1 -[(3S)-2-hydroxyletrahydrofuran-3-yl]- N^2 -((2S)-2-{[(40H-phenothiazin-2-yloxy)acetyl]amino}butanoyl)-L-leucinamide;
- N-[(10H-phenothiazin 2-yloxy)acetyl]-L-norvalyl-N¹ [(38)-2-hydroxytetrahydrofuran-3-yl)-L-leucinamide;
- N-[(10H-phenothiazin-2-yloxy)acetyl]-L-seryl-N'-((3S)-2-hydroxytefrahydrofu an-3-yl]-L-leavinamide;

or a salt thereof.

```
- N-[(10H-phenothiszin-2 yloxy)acctyl]-1-threonyl-N<sup>1</sup>-[(3S)-2-liydroxyletrahydrofuran-
  3-yl]-L-leucinamide;
 - N^1-[(3S)-2-hydroxytetrahydrofuran-3-yl]-N^2-((2S)-2-{[(10H-phenoth)azin-1-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S)-2-yl]-N^2-((2S
  2-yloxy)acetyl]amino)-2-phonylethanoyl)-L-leucinamide;
 - \mathbb{N}^1-{(3S)-2-hydroxytetrahydrofugan-3-yl]-\mathbb{N}^2-((2S)-2-{{(10H-phenothiozin-2-yloxy)-
  ncetyf]amino}hut-3-enoyl)-L-leucinamide:
  - 2-methyl-N-[(10H-phenothiaziu-2-yloxy)acetyl]şlanyl-
  N^{1}-[(38)-2-hydroxytetralnydroforan-3-yl]-L-leucinomide;

    N-[(ffH-phenothiazin-2-yloxy)acetyl]glycyl-N<sup>1</sup>-f(3S) 2-hydroxytetrahydrofuran-

  3-yl]-L-valinamide;
  - N-[(10H-phenothiazin-2-yloxy)acetyl]glycyl-3 cyclohexyl-
  \mathbb{N}^{1}-[(3S)-2-hydsoxyletrabydrofilm: 3-yl]-Lalaninamide;
  - N-[(1011-phonothiazin-2-yloxy)acctyl]glycyl-N ((3S)-2-hydroxytetiahydrofuran-3-yl]-
  L-phenyialaninamide;
    N [(10H-phenothiazin-2-yloxy)acetyl]glycyi-N'-[(3S)-2-laydroxytetrahydrofuran-
 3-yI]-№<sup>2</sup>-isobutylglycinamide;
 - N-[2-methyl-2-(10H-phenothiazin-2-yloxy)propanoyl]glycyl-
N<sup>1</sup> {(3S)-2-methoxytetrahydrofuran-3-yl}-L-leucinamide;
- N-[2-methyl-2-(10H-phenothlazin-2-yloxy)propanoyljglycyl-
N^{1}-[(3S)-2-hydroxytetrahydrofuran-3-yl]-L-leucinamide;
- N-(10,11-dihydro-5H-dihenzo[b,f]szepin-3-yleszbonyl}-L/leucyl-
N^{1}-\{(38)-2-methoxy(ctrahydrofuran-3-yl]-1>leucinamide;
   N (10,11-dihydro-5H-dibenzo(b,f]azepin-3-ylcarbonyl)-L-Isuvy)-
N<sup>1</sup> [(3$) 2 hydroxytetrahydrofuran 3 yl] L leucinamide;
- N-[(5-acetyl-10,)1-dihydro-5H-dibenzo[b,f]azepin-3-yl)carbunyl]-L-lencyl-
N<sup>1</sup> [(3S) 2 methoxytetrahydrofuran 3-yl] L Jeucinamide;
- 2-methyl-N-[(10H-phenothiazin-2-yloxy)acetyl]alanyl-
\mathbb{N}^1-[(3S)-2-hydroxytetrallydrofuran-3-yl]-L-[eucinamide sand
```

Application/Control Number: 10/532,731 Page 8

Art Unit: 1624

Conclusion

2. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Kahsay Habte whose telephone number is (571) 272-

0667. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, James O. Wilson can be reached at (571) 272-0661. The fax phone

number for the organization where this application or proceeding is assigned is (571)-

273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

/Kahsay T. Habte/

Primary Examiner, Art Unit 1624

June 13, 2008

Application/Control Number: 10/532,731

Page 9